<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03747003</url>
  </required_header>
  <id_info>
    <org_study_id>15/13</org_study_id>
    <nct_id>NCT03747003</nct_id>
  </id_info>
  <brief_title>Gonadal Function in Young to Middle Aged HIV-infected Men</brief_title>
  <official_title>Gonadal Function in Young to Middle Aged HIV-infected Men Assessed by Isotopic Dilution-liquid Chromatography-mass Spectrometry (ID-LC-MS/MS) and Chemiluminescent Immunoassay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria di Modena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria di Modena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV infection is associated to premature decline of serum testosterone. However, prevalence
      and biochemical characterization of hypogonadism in HIV-infected men are still to be well
      defined. HIV-infection is strongly associated to erectile dysfunction in men, but preliminary
      data suggest that it is poorly associated with serum testosterone in this context.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the gonadal function of young to middle aged
      HIV-infected men in order to characterize hypogonadism by assessing circulating total
      testosterone with either Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) or
      chemiluminescent immunoassay. Furthermore, secondary aim is to assess the erectile function
      through the use of validated questionnaires (International Index of Erectile Function (IIEF)
      15 and 5).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum total testosterone</measure>
    <time_frame>Assessed only once at the moment of enrollment with liquid chromatography tandem mass spectrometry</time_frame>
    <description>From blood sample - unit of measurement ng/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum total testosterone</measure>
    <time_frame>Assessed only once at the moment of enrollment with chemiluminiscent immunoassay</time_frame>
    <description>From blood sample - unit of measurement ng/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum free testosterone</measure>
    <time_frame>Calculated only once at the moment of enrollment</time_frame>
    <description>Calculated formula (Vermeulen equation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score at IIEF questionnaire</measure>
    <time_frame>Assessed only once at the moment of enrollment</time_frame>
    <description>Total score at erectile function domain of IIEF-15 questionnaire</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">315</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Hypogonadism, Male</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>HIV-infected male patients</arm_group_label>
    <description>Male patients (age 18-50 years) with HIV-infection and ongoing HAART therapy No intervention is provided</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention is provided</intervention_name>
    <description>No intervention is provided</description>
    <arm_group_label>HIV-infected male patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample for hormonal assay
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of Young-to-Middle Aged HIV-infected Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male gender

          -  Age 18-50 years

          -  HIV-infection

          -  Ongoing Highly Active Antiretroviral Therapy

        Exclusion Criteria:

          -  Previous treatment with androgens, anti-androgens

          -  Severe liver insufficiency

          -  Severe renal insufficiency
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria di Modena</investigator_affiliation>
    <investigator_full_name>Vincenzo Rochira</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

